NYBC Ventures

The investment team listed on the firm's website includes Christopher D. Hillyer, Jay Mohr, Meg Wood, and Kuan Yu. Specific titles and individual authorities are not publicly detailed. A separate board of managers—John Rosenthal, Jung Choi, Cristina Csimma, and David Kabakoff—provides governance oversight for the entity.

NYBC Ventures was launched by New York Blood Center Enterprises with a $50M sponsor commitment. The parent organization is a 60-year-old non-profit that runs blood collection, the Lindsley F. Kimball Research Institute, and Comprehensive Cell Solutions, a cell-and-gene therapy CDMO. The venture arm was created to commercialize innovations emerging from that research and clinical ecosystem.

The firm targets early to mid-stage innovations according to its published strategy. It invests in therapeutics, devices, and other breakthrough technologies within hematology, transfusion medicine, cell therapy, and infectious disease. It has not disclosed whether allocations are structured as equity, convertibles, or alternative deal structures.

The firm's published materials describe a direct investment strategy targeting therapeutics, devices, and enabling technologies. There is no mention of fund-of-funds commitments, co-investment vehicles, or special-purpose vehicles in any publicly available source.

The disclosed $50M capital commitment comes from New York Blood Center Enterprises, the non-profit sponsor. There is no evidence of external limited partners, endowment capital, or additional LP closings in publicly available sources. The firm has not disclosed fee structures or carry arrangements.